FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma

The U.S. FDA today approved Genetech’s Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be...

Epizyme’s Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA

Epizyme, Inc., a Cambridge-based clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced that the U.S. FDA has granted orphan drug status to the company's first-in-class EZH2 inhibitor, tazemetostat,...

FDA Grants Accelerated Approval to New Treatment for Advanced Soft Tissue Sarcoma

On October 19, the U.S. Food and Drug Administration announced it has granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS),...

FDA Approves Amgen’s New Cholesterol-Lowering Medication Repatha™ (evolocumab)

Global pharmaceutical company Amgen announced that the U.S. FDA has approved its new cholesterol-lowering drug, Repatha™ (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Life Science Leaders Celebrate Global Partnerships During WuXi Global Forum 2018

More than 2,000 life science industry insiders around the globe participated in the WuXi Global Forum on Jan. 9, 2018 during the annual J.P....

WuXi Global Forum 2018